Study guide
4.2 Sepsis and Septic Shock Management
Certified Flight Paramedic FP-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Safety and Transport
1.1 Pre-Flight Operations and Equipment Stowing 1.2 Scene Safety and Landing Zone Management 1.3 In-Flight Emergency Response and Abort Protocols 1.4 Post-Incident Survival and Rescue Operations
2 Chapter 2: Flight Physiology
2.1 Gas Laws in Transport Medicine 2.2 Hypoxia: Classification and Corrective Actions 2.3 Environmental Stressors of Flight and Cabin Pressurization
3 Chapter 3: Airway, Anesthesia, and Analgesics
3.1 Advanced Airway Assessment and Difficult Airway Algorithms 3.2 Rapid Sequence Intubation (RSI) and Medication Selection 3.3 Mechanical Ventilation: Modes, Settings, and Monitoring 3.4 Transport Oxygen Systems and Duration Calculations 3.5 Anaesthetics and Induction Agents 3.6 Neuromuscular Blocking Agents 3.7 Analgesics and Vasoactive Sedative Titration
4 Chapter 4: Medical Emergencies
4.1 Respiratory Failure Pathologies (ARDS, Asthma, COPD) 4.2 Sepsis and Septic Shock Management 4.3 Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) 4.4 Toxicological Emergencies and Overdose Antidotes 4.5 Environmental Emergencies: Core Temperature Control (Hypo/Hyperthermia) 4.6 Adrenal Crisis and Incretin/Endocrine Emergencies
5 Chapter 5: Neurological Emergencies
5.1 Neurological Assessment and GCS Motor Scales 5.2 Traumatic Brain Injury (TBI) and Intracranial Pressure (ICP) Management 5.3 Stroke Care: Hemorrhagic vs. Ischemic Thrombectomy Candidates 5.4 Status Epilepticus Seizure Protocols 5.5 Spinal Trauma and Spinal Cord Syndromes
6 Chapter 6: Cardiac Emergencies
6.1 Acute Coronary Syndrome (ACS) and 12-Lead Interpretation 6.2 Dysrhythmias: Bradycardias and High-Grade AV Blocks 6.3 Cardiogenic Shock and Systemic Vascular Resistance (SVR) 6.4 Vasoactive Medication Titration (Norepinephrine, Epinephrine, Dopamine) 6.5 Mechanical Circulatory Support (IABP and ECMO Transport) 6.6 Post-Cardiac Arrest Care and Targeted Temperature Management
7 Chapter 7: Trauma/Burn Resuscitation
7.1 Damage Control Resuscitation and the Lethal Triad 7.2 Hemorrhage Control and Massive Transfusion Protocols (MTP) 7.3 Penetrating Thoracic Trauma and Cardiac Tamponade (Beck's Triad) 7.4 Blunt Force Deceleration Injuries (Traumatic Aortic Rupture) 7.5 Burn Physiology: Calculations (Parkland Formula) and Escharotomy
8 Chapter 8: Maternal, Fetal, and Neonatal Emergencies
8.1 Perinatal Transport and Maternal Complications 8.2 Ob/Gyn Emergencies and Emergency Delivery 8.3 Neonatal Resuscitation Program (NRP) Standards
9 Chapter 9: Pediatric Emergencies
9.1 Pediatric Assessment Triangle and Pathophysiology 9.2 Pediatric Airway and Ventilatory Management 9.3 Pediatric Pharmacology and Dosing Calculations 9.4 Pediatric Trauma and Resuscitation
10 Chapter 10: Professional Considerations
10.1 CAMTS Standards and Quality Metrics 10.2 Medical Ethics and Transport Law (EMTALA) 10.3 Crew Resource Management (CRM) and Human Factors
4.2 Sepsis and Septic Shock Management
Key Takeaways Explain This Topic AI
Sepsis is defined as life-threatening organ dysfunction, identified by a SOFA score increase of 2 points or more, while septic shock requires vasopressors for MAP >= 65 mmHg and has a lactate > 2 mmol/L despite fluid resuscitation.
The 1-Hour Sepsis Bundle mandates measuring lactate (re-measuring if >2 mmol/L), obtaining blood cultures before broad-spectrum antibiotics, administering 30 mL/kg crystalloids, and starting vasopressors for refractory hypotension.
Norepinephrine is the first-line vasopressor in septic shock, acting as a potent alpha-1 agonist, while Vasopressin is a second-line fixed-dose V1 agonist adjunct.
Early Goal-Directed Therapy (EGDT) parameters include CVP 8-12 mmHg (12-15 mmHg if ventilated), MAP >= 65 mmHg, urine output >= 0.5 mL/kg/hr, ScvO2 >= 70%, and lactate clearance >= 10% every 2 hours.
Balanced crystalloids (such as Lactated Ringer's) are preferred over 0.9% Normal Saline for resuscitation to reduce the incidence of hyperchloremic metabolic acidosis and renal injury.
Last updated: July 2026
- Sepsis and Septic Shock Management
- Pathophysiology and Clinical Definitions
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Pathophysiologically, the release of pro-inflammatory mediators triggers widespread endothelial injury, capillary leak, and activation of the coagulation cascade. This results in microvascular thrombosis, tissue hypoperfusion, and cytopathic dysoxia (inability of cells to utilize oxygen).
Organ dysfunction is clinically identified by an acute increase of 2 points or more in the Sequential Organ Failure Assessment (SOFA) score, which evaluates the respiratory, coagulation, hepatic, cardiovascular, central nervous, and renal systems. In out-of-hospital or transport environments, the quick SOFA (qSOFA) is a rapid screening tool. A patient meets qSOFA criteria if they have 2 or more of the following:
- Respiratory rate >= 22 breaths per minute
- Altered mental status (GCS < 15)
- Systolic blood pressure <= 100 mmHg
Septic Shock is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. It is clinically defined as sepsis requiring vasopressor therapy to maintain a Mean Arterial Pressure (MAP) >= 65 mmHg AND a serum lactate level > 2 mmol/L despite adequate fluid resuscitation.
The Surviving Sepsis 1-Hour Bundle
The Surviving Sepsis Campaign recommends initiating resuscitation and treatment within one hour of recognition. The five key elements of the 1-Hour Bundle are:
Measure Lactate Level: A lactate level > 2 mmol/L indicates tissue hypoperfusion. Re-measure lactate within 2–4 hours if the initial level was elevated (> 2 mmol/L) to guide resuscitation.
Obtain Blood Cultures: Draw at least two sets of blood cultures (one percutaneous and one from each vascular access device in place for > 48 hours) prior to administering antibiotics. However, do not delay antibiotic therapy if cultures cannot be rapidly obtained.
Administer Broad-Spectrum Antibiotics: Initiate empiric broad-spectrum IV antibiotics (e.g., Cefepime, Piperacillin/Tazobactam, or Meropenem, often paired with Vancomycin for MRSA coverage) to target the suspected source.
Begin Fluid Resuscitation: Administer 30 mL/kg of IV crystalloid fluid for patients presenting with hypotension (MAP < 65 mmHg) or severe hypoperfusion (lactate >= 4 mmol/L). Balanced crystalloids (such as Lactated Ringer's or Plasma-Lyte) are preferred over 0.9% Normal Saline to reduce the risk of hyperchloremic metabolic acidosis and acute kidney injury.
Initiate Vasopressors: Apply vasopressors immediately if the patient remains hypotensive during or after the 30 mL/kg fluid challenge to maintain a MAP >= 65 mmHg.
Early Goal-Directed Therapy (EGDT) and Resuscitation Targets
Although large clinical trials (ProCESS, ARISE, ProMISe) demonstrated that protocolized EGDT does not show a survival benefit compared to usual care when antibiotics and fluids are delivered promptly, the physiological targets of EGDT remain core concepts on the FP-C exam:
Central Venous Pressure (CVP): Target 8–12 mmHg (12–15 mmHg if mechanically ventilated to account for positive pressure). CVP is a surrogate for right atrial pressure and volume status.
Mean Arterial Pressure (MAP): Target >= 65 mmHg.
Urine Output: Target >= 0.5 mL/kg/hour (measured via indwelling Foley catheter).
Central Venous Oxygen Saturation (ScvO2): Target >= 70% (measured from a central venous catheter in the superior vena cava) or Mixed Venous Oxygen Saturation (SvO2) >= 65%. A low ScvO2 indicates inadequate oxygen delivery (low cardiac output or low hemoglobin) relative to tissue demand.
Lactate Clearance: Target a decrease of >= 10% in serum lactate every 2 hours until lactate is normalized (< 2 mmol/L).
Vasoactive and Inotropic Therapy in Transport
When fluid resuscitation fails to restore blood pressure and perfusion, vasoactive medications must be titrated to clinical endpoints:
Norepinephrine (Levophed): First-line vasopressor for septic shock. Potent alpha-1 adrenergic receptor agonist (vasoconstriction) with modest beta-1 agonist activity (increasing heart rate and contractility).
Dosing: 0.05–1.0 mcg/kg/min (or 2–30 mcg/min).
Vasopressin (Pitressin): Second-line adjunct. Stimulates V1 receptors on vascular smooth muscle, causing direct vasoconstriction. Administered at a fixed, non-titratable rate of 0.03–0.04 units/min. Helps reduce norepinephrine dosing and limits beta-adrenergic side effects.
Epinephrine: Second-line alternative. Strong alpha-1, beta-1, and beta-2 agonist activity, which increases cardiac output and systemic vascular resistance but may increase serum lactate levels due to beta-2 mediated aerobic glycolysis.
Dobutamine: Inotrope indicated in patients with persistent tissue hypoperfusion (low ScvO2 < 70%) despite achieving an adequate MAP and CVP, indicating myocardial dysfunction. Acts primarily on beta-1 receptors to increase cardiac contractility.
Hydrocortisone: Indicated at 200 mg/day IV only for patients with septic shock who remain hemodynamically unstable despite adequate fluid resuscitation and vasopressor therapy (suspected relative adrenal insufficiency).
Transport Considerations
Vascular Access: Central access is preferred for vasopressor infusion. However, do not delay the initiation of vasopressors. Infusing Norepinephrine through a large-bore peripheral IV (18G or larger, located in the antecubital fossa) is safe and recommended during transport until central access is secured.
Monitoring: Continuous invasive blood pressure monitoring via an arterial line is the gold standard during transport of patients on vasoactive infusions.
Fluid Balance: Avoid aggressive fluid administration beyond the initial 30 mL/kg unless the patient shows clear signs of fluid responsiveness. Positive fluid balance is associated with worsening lung injury (ARDS) and increased mortality.
Vasoactive Comparison Table
Vasoactive Agent Primary Receptor Activity Physiologic Effect Clinical Indication
Norepinephrine α1 > β1 Widespread vasoconstriction, mild increase in contractility First-line vasopressor for septic shock
Vasopressin V1 receptors Direct smooth muscle vasoconstriction Second-line fixed-dose adjunct (0.03-0.04 units/min)
Epinephrine α1, β1, β2 Widespread vasoconstriction, increased contractility and heart rate Second-line agent; can increase lactate levels
Dobutamine β1 > β2 Increased myocardial contractility, mild vasodilation Inotrope for sepsis-induced myocardial dysfunction
Hydrocortisone Glucocorticoid receptor Restores vascular responsiveness to catecholamines Refractory shock despite fluids and vasopressors